Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rocky Mountain Cancer Centers
Denver, Colorado, United States
- Florida Cancer Specialists-South
Fort Myers, Florida, United States
- Florida Hospital Cancer Institute
Orlando, Florida, United States
- Florida Cancer Specialists-North
St. Petersburg, Florida, United States
- Ingalls Cancer Research Center
Harvey, Illinois, United States
- Research Medical Center
Kansas City, Missouri, United States
- Oncology Hematology Care
Cincinnati, Ohio, United States
- Spartanburg Medical Center/gibbs Cancer Center
Spartanburg, South Carolina, United States
- Tennessee Oncology
Chattanooga, Tennessee, United States
- Tennessee Oncology Pllc
Nashville, Tennessee, United States
- Center for Cancer and Blood Disorders
Fort Worth, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 May 2015
- Primary completion
- 21 May 2021
- Completion
- 21 May 2021
- Last update posted
- 1 Jul 2022
- Registered enrollment
- 65
- Registry id
- NCT02317991
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.